Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.45 |
| ▸ | CDK7 | P50613 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802594 | 0.97 | KDR (1.00) | KDRHRH4CHEK1CDK7 | |
| SCHEMBL5889166 | 0.91 | KDR (0.83) | KDRCHEK1 | |
| SCHEMBL5889168 | 0.90 | KDR (0.81) | KDRCHEK1 | |
| SCHEMBL5889029 | 0.83 | KDR (0.84) | KDRCHEK1 | |
| SCHEMBL5889043 | 0.83 | KDR (1.00) | KDRHRH4 | |
| SCHEMBL5889039 | 0.82 | KDR (1.00) | KDRCHEK1 | |
| SCHEMBL6808204 | 0.81 | KDR (1.00) | KDR | |
| SCHEMBL6802538 | 0.81 | KDR (0.76) | KDR | |
| SCHEMBL5889186 | 0.81 | KDR (1.00) | KDRCHEK1 | |
| SCHEMBL7691786 | 0.81 | KDR (0.76) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885HRH4 4015/4885CHEK1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.